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Introduction
Looking back over 2003, two themes have dominated the
critical care literature. The year started with severe acute
respiratory syndrome and ended with reports of an influenza
epidemic. In between, the threat of a biological weapon
attack escalated then, thankfully, rescinded. The second
theme has been the publication of trials re-investigating areas
of ongoing controversy, especially in the final 2 months.
The pulmonary artery catheter is safe, but is it
useful?
Since 1996, when Connors and colleagues published data
suggesting right heart catheterisation in critically ill patients
was associated with an increase in mortality [1], there has
been a heated debate about the dangers and benefits of this
monitoring intervention. December saw the publication of two
further large-scale, multicentre trials into the use of
pulmonary artery catheters.
An American group published data from 1010 intensive care
unit admissions with severe sepsis and performed a complex
series of analyses having case-matched a subset from their
prospective cohort [2]. They did not detect any significant
differences in either inhospital mortality, length of stay or cost
between patients who had or who had not had a pulmonary
artery catheter.
In the second, French, study, 676 patients with either shock,
acute respiratory distress syndrome (ARDS) or both, were
randomised to receive or not a pulmonary artery catheter [3].
Again, no difference in morbidity or mortality (up to 90 days)
was found. Although fault can be found with the design of
both of these trials, there can surely be no doubt remaining
regarding the safety of inserting a piece of sterile plastic into
the pulmonary artery. There remains, however, a lack of
evidence that the monitoring provided by pulmonary artery
catheters, or indeed other cardiac output monitoring devices,
results in improvements in outcome. Arguably this reflects the
controversies regarding optimal cardiovascular management
rather than any intrinsic problem with flow monitoring.
The murky world of the recruitment
manoeuvre
The ARDSnet group continue in their quest to direct the
optimal ventilatory management of ARDS patients with the
publication of their trial into the safety and efficacy of a daily
recruitment manoeuvre [4]. They used a subset of low versus
high positive end-expiratory pressure trial patients, taking all
subjects from those randomised to the high positive end-
expiratory pressure group. For their manoeuvre they chose a
30s sustained inflation to 35–40cmH2O. The group studied
72 patients using a crossover design and performed one
manoeuvre every 24 hours, alternating real and sham. The
study produced no convincing or coherent results. The
authors concluded that further studies are required.
Surely, to be of any benefit, recruitment manoeuvres need to
be performed far more regularly than once every 48 hours,
and some would argue that 30s is insufficient, advocating a
minimum of 90s. Advocates of adding a sigh to ventilatory
strategies and those now evolving the optimal use of high-
frequency oscillatory techniques have shown how long
recruitment can take and how quickly de-recruitment ensues.
Yet another reason to get out the noninvasive
ventilator?
Few would argue that noninvasive pressure support
ventilation is the optimal modality in acute hypercapnic
respiratory failure in chronic obstructive pulmonary disease
patients. However, enthusiasm for this technique in other
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pathologies has been tempered by more mixed results in
other patient groups. An Italian group has just published a
randomised control trial of noninvasive pressure support
ventilation in 130 patients with cardiogenic pulmonary
oedema [5]. They found an improvement in short-term
physiological parameters but the intubation rate, the
inhospital mortality and the length of stay were no different
between the study and control groups. Subgroup analysis
however, did find a statistically significant reduction in the
intubation rate in patients with hypercapnia at presentation
(two of 33 versus nine of 31). As experience with this
technique continues to develop and the technology,
especially the mask/patient interface, improves, I am certain
that it will become the first-line therapy for all patients with
type II respiratory failure.
Satisfying the critics?
Minimising sedation has clear and tangible benefits [6,7].
However, strategies that advocate cessation of drug therapy
until emergence have been criticised for exposing patients to
unnecessary psychological trauma. In a follow-up to their
study of daily sedative cessation, Kress and colleagues have
published a study of follow-up data on a limited number of
their patients [8]. Although the numbers involved are
comparatively small, the data show, if anything, less
psychological sequelae in the treatment group than in the
control group.
Less is more
Further evidence in support of this philosophy, especially in
the context of duration of antimicrobial therapy, comes from a
large French study [9]. The investigators randomised
401 patients with ventilator-associated pneumonia to receive
either 8 or 15 days of optimal antibiotic therapy. There were
no differences in any of the major clinical outcome measures
between the groups. Taken together with previous smaller
studies into the optimal duration of antibiotic therapy, it would
appear that a short duration of high-dose therapy is the
optimal strategy. How short is short will require further
investigation.
Carbon dioxide: the new therapy for ARDS?
Laffey and colleagues have been publishing research papers
extolling the virtues of hypercapnia for the past few years. To
add yet further credence to their hypothesis, they have
published two further studies in laboratory animals to support
the case for a trial of therapeutic hypercapnia in ARDS
patients [10,11]. In light of the ongoing debate about
permissive hypercapnia, and in particular the timing and
efficacy of bicarbonate therapy/haemofiltration to treat the
resulting acidosis, this simple and free approach certainly
warrants study in patients.
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